207 related articles for article (PubMed ID: 37410149)
1. It is time to implement molecular classification in endometrial cancer.
Bruno V; Logoteta A; Chiofalo B; Mancini E; Betti M; Fabrizi L; Piccione E; Vizza E
Arch Gynecol Obstet; 2024 Mar; 309(3):745-753. PubMed ID: 37410149
[TBL] [Abstract][Full Text] [Related]
2. High risk endometrial cancer: Clues towards a revision of the therapeutic paradigm.
Bendifallah S; Ilenko A; Daraï E
J Gynecol Obstet Hum Reprod; 2019 Dec; 48(10):863-871. PubMed ID: 31176047
[TBL] [Abstract][Full Text] [Related]
3. Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: Results from the FRANCOGYN study Group.
Bendifallah S; Ouldamer L; Lavoue V; Canlorbe G; Raimond E; Coutant C; Graesslin O; Touboul C; Collinet P; Daraï E; Ballester M;
Gynecol Oncol; 2017 Jan; 144(1):107-112. PubMed ID: 27789083
[TBL] [Abstract][Full Text] [Related]
4. Pattern of recurrence in patients with endometrial cancer: A retrospective study.
Vizza E; Cutillo G; Bruno V; Sperduti I; Mancini E; Baiocco E; Chiofalo B; Cicchillitti L; Certelli C; Zampa A; Piccione E; Corrado G
Eur J Surg Oncol; 2020 Sep; 46(9):1697-1702. PubMed ID: 32204935
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
Vrede SW; van Weelden WJ; Visser NCM; Bulten J; van der Putten LJM; van de Vijver K; Santacana M; Colas E; Gil-Moreno A; Moiola CP; Mancebo G; Krakstad C; Trovik J; Haldorsen IS; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; van der Wurff AA; Matias-Guiu X; Amant F; ; Snijders MPLM; Küsters-Vandevelde HVN; Reijnen C; Pijnenborg JMA
Gynecol Oncol; 2021 Jun; 161(3):787-794. PubMed ID: 33858677
[TBL] [Abstract][Full Text] [Related]
6. Call for Surgical Nodal Staging in Women with ESMO/ESGO/ESTRO High-Intermediate Risk Endometrial Cancer: A Multicentre Cohort Analysis from the FRANCOGYN Study Group.
Ouldamer L; Bendifallah S; Body G; Canlorbe G; Touboul C; Graesslin O; Raimond E; Collinet P; Coutant C; Lavoué V; Lévêque J; Daraï E; Ballester M;
Ann Surg Oncol; 2017 Jun; 24(6):1660-1666. PubMed ID: 28058558
[TBL] [Abstract][Full Text] [Related]
7. Abnormal preoperative haematological parameters in Endometrial cancer; reflecting tumour aggressiveness or reduced response to radiotherapy?
Vrede SW; Donkers H; Reijnen C; Smits A; Visser NCM; Geomini PM; Ngo H; van Hamont D; Pijlman BM; Vos MC; Snijders MPLM; Kruitwagen R; Bekkers RLM; Galaal K; Pijnenborg JMA
J Obstet Gynaecol; 2024 Dec; 44(1):2294332. PubMed ID: 38186008
[TBL] [Abstract][Full Text] [Related]
8. Concordance between preoperative ESMO-ESGO-ESTRO risk classification and final histology in early-stage endometrial cancer.
Daix M; Angeles MA; Migliorelli F; Kakkos A; Martinez Gomez C; Delbecque K; Mery E; Tock S; Gabiache E; Decuypere M; Goffin F; Martinez A; Ferron G; Kridelka F
J Gynecol Oncol; 2021 Jul; 32(4):e48. PubMed ID: 33908709
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma.
Raffone A; Travaglino A; Raimondo D; Neola D; Renzulli F; Santoro A; Insabato L; Casadio P; Zannoni GF; Zullo F; Mollo A; Seracchioli R
Gynecol Oncol; 2021 Aug; 162(2):401-406. PubMed ID: 34088515
[TBL] [Abstract][Full Text] [Related]
10. [European guidelines (ESMO-ESGO-ESTRO consensus conference) for the management of endometrial cancer].
Ballester M; Bendifallah S; Daraï E
Bull Cancer; 2017 Dec; 104(12):1032-1038. PubMed ID: 29173977
[TBL] [Abstract][Full Text] [Related]
11. The impact of the type of nodal assessment on prognosis in patients with high-intermediate and high-risk ESMO/ESGO/ESTRO group endometrial cancer. A multicenter Italian study.
Buda A; Restaino S; Di Martino G; De Ponti E; Monterossi G; Dinoi G; Magni S; Quagliozzi L; Dell'Orto F; Ciccarone F; Lamanna M; Scambia G; Landoni F; Fanfani F
Eur J Surg Oncol; 2018 Oct; 44(10):1562-1567. PubMed ID: 30077521
[TBL] [Abstract][Full Text] [Related]
12. A clue towards improving the European Society of Medical Oncology risk group classification in apparent early stage endometrial cancer? Impact of lymphovascular space invasion.
Bendifallah S; Canlorbe G; Raimond E; Hudry D; Coutant C; Graesslin O; Touboul C; Huguet F; Cortez A; Daraï E; Ballester M
Br J Cancer; 2014 May; 110(11):2640-6. PubMed ID: 24809776
[TBL] [Abstract][Full Text] [Related]
13. FIGO staging of endometrial cancer: 2023.
Berek JS; Matias-Guiu X; Creutzberg C; Fotopoulou C; Gaffney D; Kehoe S; Lindemann K; Mutch D; Concin N;
Int J Gynaecol Obstet; 2023 Aug; 162(2):383-394. PubMed ID: 37337978
[TBL] [Abstract][Full Text] [Related]
14. Change in hazard rates of recurrence over time following diagnosis of endometrial cancer: An age stratified multicentre study from the FRANCOGYN group.
Ouldamer L; Bendifallah S; Body G; Canlorbe G; Touboul C; Graesslin O; Raimond E; Collinet P; Coutant C; Lavoué V; Lévêque J; Bricou A; Huchon C; Daraï E; Ballester M;
Eur J Surg Oncol; 2018 Dec; 44(12):1914-1920. PubMed ID: 30217355
[TBL] [Abstract][Full Text] [Related]
15. Preoperative MR imaging for ESMO-ESGO-ESTRO classification of endometrial cancer.
Lavaud P; Fedida B; Canlorbe G; Bendifallah S; Darai E; Thomassin-Naggara I
Diagn Interv Imaging; 2018 Jun; 99(6):387-396. PubMed ID: 29472031
[TBL] [Abstract][Full Text] [Related]
16. Endometrial cancer risk factors, treatment, and survival outcomes as per the European Society for Medical Oncology (ESMO) - European Society of Gynaecological Oncology (ESGO) - European Society for Radiotherapy and Oncology (ESTRO) risk groups and International Federation of Gynecology and Obstetrics (FIGO) staging: An experience from developing world.
Gupta N; Pandey A; Dimri K; Sehgal A; Bhagat R; Suraj ; Gill G
J Cancer Res Ther; 2023; 19(3):701-707. PubMed ID: 37470597
[TBL] [Abstract][Full Text] [Related]
17. Machine learning endometrial cancer risk prediction model: integrating guidelines of European Society for Medical Oncology with the tumor immune framework.
Bruno V; Betti M; D'Ambrosio L; Massacci A; Chiofalo B; Pietropolli A; Piaggio G; Ciliberto G; Nisticò P; Pallocca M; Buda A; Vizza E
Int J Gynecol Cancer; 2023 Nov; 33(11):1708-1714. PubMed ID: 37875322
[TBL] [Abstract][Full Text] [Related]
18. Evolution of adjuvant treatment in endometrial cancer-no evidence and new questions?
Marnitz S; Köhler C; Gharbi N; Kunze S; Jablonska K; Herter J
Strahlenther Onkol; 2018 Nov; 194(11):965-974. PubMed ID: 30112692
[TBL] [Abstract][Full Text] [Related]
19. Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis.
Nero C; Pasciuto T; Cappuccio S; Corrado G; Pelligra S; Zannoni GF; Santoro A; Piermattei A; Minucci A; Lorusso D; Fanfani F; Scambia G
Cancer; 2022 Aug; 128(15):2898-2907. PubMed ID: 35617463
[TBL] [Abstract][Full Text] [Related]
20. Endometrial cancer: prognostic significance of risk classification based on pre-intraoperative findings.
Maneschi F; Ceccacci I; Perugini A; Pane C; Simeone A; Manicone A
Arch Gynecol Obstet; 2012 Feb; 285(2):521-7. PubMed ID: 21779772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
